Stereotaxis And 3 Other Stocks Under $2 Insiders Are Aggressively Buying

Author: Lisa Levin | August 29, 2023 09:21am

The Dow Jones closed higher by more than 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

ReWalk Robotics

• The Trade: ReWalk Robotics Ltd. (NASDAQ:RWLK) 10% owner Lind Global Fund II LP acquired a total of 29,545 shares an average price of $0.62. To acquire these shares, it cost around $18,368.
• What’s Happening: ReWalk Robotics announced closing of the previously announced acquisition of AlterG, Inc.
• What ReWalk Robotics Does: ReWalk Robotics Ltd is an Israel based medical device company. It is engaged in designing, developing and commercializing the Rewalk systems which are exoskeletons allowing wheelchair-bound individuals to stand and walk once again.

VolitionRx

• The Trade: VolitionRx Limited (NYSE:VNRX) Chief Scientific Officer Jacob Vincent Micallef acquired a total of 20,000 shares at an average price of $1.24. The insider spent around $24,800.
• What’s Happening: The company said cash and cash equivalents as of June 30, 2023, totaled around $19.7 million versus $10.9 million at the end of 2022.
• What VolitionRx Does: VolitionRX Ltd is a United states based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19.

DBV Technologies

• The Trade: DBV Technologies S.A. (NASDAQ:DBVT) Director Timothy Morris acquired a total of 12,000 shares at an average price of $1.52. To acquire these shares, it cost around $18,240.
• What’s Happening: DBV closed the second quarter with a cash balance of $174 million.
• What DBV Technologies Does: DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin.

Check This Out: Fear & Greed Index Remains In 'Neutral' Zone Ahead Of Jobs Data

Don’t forget to check out our premarket coverage here

Stereotaxis

• The Trade: Stereotaxis, Inc. (NYSE:STXS) Director Paul J Isaac acquired a total of 9,000 shares at an average price of $1.74. The insider spent $15,670 to buy those shares.
• What’s Happening: Stereotaxis reported a 28% revenue growth in the second quarter.
• What Stereotaxis Does: Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures.

Posted In: DBVT RWLK STXS VNRX